Close Menu
February 05, 2020
Sponsored by
LGC

Development of a Novel Multiplex Assay: A Partnership Case Study

GenomeWebinar

Senior Scientist, R&D Group, Co-Diagnostics 

Head of Business Development, Co-Diagnostics

General Manager, Magna Mosquito Abatement District

This webinar provides a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.          

A pivotal part of the molecular diagnostics innovation chain that is often overlooked is the relation between critical component suppliers, test manufacturers, and end users. This webinar addresses the development and utility of an innovative multiplex application for detection of Zika, dengue and chikungunya in mosquitos, enabling communities to reduce infection rates by vector control and prevent unnecessary infections and subsequent treatments.

Dr. Jana Kent, Senior Research Scientist from Co-Diagnostics (CoDx), will introduce the company’s CoPrimer technology, which provides flexibility in multiplex assay design without cross-reactivity or non-specific amplification (i.e. primer dimers). She shares insights on the development process of the Zika, dengue and chikungunya test and highlight best practices when working with critical component suppliers and end users.

Next, Ryan Lusty, General Manager of the Magna Mosquito Abatement District in Utah, discusses the implementation of this test in his county and how it impacted healthcare outcomes. Ryan discusses the importance of same-day test results for vector control, as opposed to waiting several days for state lab results.                    

Joseph Featherstone from CoDx wraps up by addressing the importance of partnership for the success of innovation, development, and commercialization of molecular diagnostics and will present opportunities for new research and commercial applications.

Sponsored by

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.